nach oben

Current Obesity Reports

Erschienen in:

06.07.2023 | REVIEW

Obesity and Dyslipidemia: A Review of Current Evidence

verfasst von: Jelena Vekic, Aleksandra Stefanovic, Aleksandra Zeljkovic

Erschienen in: Current Obesity Reports | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Obesity is accompanied by atherogenic dyslipidemia, a specific lipid disorder characterized by both quantitative and qualitative changes of plasma lipoproteins. The main alterations in the lipid profile include hypertriglyceridemia, reduced high-density lipoprotein (HDL) cholesterol level, and elevated small dense low-density lipoprotein (LDL) particles. Epidemiological data show that obesity is more common in women and is a frequent risk factor for reproductive disorders, metabolic complications in pregnancy, and cardiometabolic disease later in life. The aim of this narrative review is to discuss recent advances in the research of dyslipidemia in obesity, with an emphasis on female-specific disorders and cardiometabolic risk.

Recent Findings

The focus of current research on dyslipidemia in obesity is moving toward structurally and functionally modified plasma lipoproteins. Special attention is paid to the pro-atherogenic role of triglyceride-rich lipoproteins and their remnants. Introduction of advanced analytical techniques enabled identification of novel lipid biomarkers with potential clinical applications. In particular, proteomic and lipidomic studies have provided significant progress in the comprehensive research of HDL’s alterations in obesity. Obesity-related dyslipidemia is a widespread metabolic disturbance in polycystic ovary syndrome patients and high-risk pregnancies, but is seldom evaluated with respect to its impact on future cardiometabolic health.

Summary

Obesity and associated cardiometabolic diseases require a more depth insight into the quality of lipoprotein particles. Further application of omics-based techniques would enable a more comprehensive evaluation of dyslipidemia in order to reduce an excessive cardiovascular risk attributable to increased body weight. However, more studies on obesity-related female reproductive disorders are needed for this approach to be adopted in daily clinical practice.

Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120–33. https://doi.org/10.1038/s41576-021-00414-z.CrossRefPubMed

Valenzuela PL, Carrera-Bastos P, Castillo-Garcia A, Lieberman DE, Santos-Lozano A, Lucia A. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol. 2023. https://doi.org/10.1038/s41569-023-00847-5.CrossRefPubMed

Lopez-Jimenez F, Almahmeed W, Bays H, Cuevas A, Di Angelantonio E, le Roux CW, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022;29(17):2218–37. https://doi.org/10.1093/eurjpc/zwac187.

Vekic J, Silva-Nunes J, Rizzo M. Glucose metabolism disorders: challenges and opportunities for diagnosis and treatment. Metabolites. 2022;12(8). https://doi.org/10.3390/metabo12080712.

Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23(2). https://doi.org/10.3390/ijms23020786.

Lorenzatti AJ, Toth PP. New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol. 2020;15:1–9. https://doi.org/10.15420/ecr.2019.06.

Vekic J, Zeljkovic A, Cicero AFG, Janez A, Stoian AP, Sonmez A, et al. Atherosclerosis development and progression: the role of atherogenic small, dense LDL. Medicina (Kaunas). 2022;58(2). https://doi.org/10.3390/medicina58020299.

Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32. https://doi.org/10.1016/j.jacc.2010.05.034.CrossRefPubMed

Lalosevic M, Kotur-Stevuljevic J, Vekic J, Rizzo M, Kosanovic T, Blagojevic IP, et al. Alteration in redox status and lipoprotein profile in COVID-19 patients with mild, moderate, and severe pneumonia. Oxid Med Cell Longev. 2022;2022:8067857. https://doi.org/10.1155/2022/8067857.CrossRefPubMedPubMedCentral

10.

Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217. https://doi.org/10.1016/j.metabol.2022.155217.

11.

World Obesity Federation. World Obesity Atlas 2023. https://s3-eu-west-1.amazonaws.com/wof-files/World_Obesity_Atlas_2023_Report.pdf. Accessed June 1 2023. .

12.

Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689–700. https://doi.org/10.1038/s41569-021-00541-4.CrossRefPubMed

13.

Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. Metabolism. 2019;92:71–81. https://doi.org/10.1016/j.metabol.2018.11.005.CrossRefPubMed

14.

Tucker S, Bramante C, Conroy M, Fitch A, Gilden A, Wittleder S, et al. The most undertreated chronic disease: addressing obesity in primary care settings. Curr Obes Rep. 2021;10(3):396–408. https://doi.org/10.1007/s13679-021-00444-y.CrossRefPubMedPubMedCentral

15.

Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex/gender differences in obesity prevalence, comorbidities, and treatment. Curr Obes Rep. 2021;10(4):458–66. https://doi.org/10.1007/s13679-021-00453-x.CrossRefPubMed

16.

Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022;7(1):216. https://doi.org/10.1038/s41392-022-01073-0.CrossRefPubMedPubMedCentral

17.

Packard CJ, Boren J, Taskinen MR. Causes and consequences of hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:252. https://doi.org/10.3389/fendo.2020.00252.CrossRefPubMed

18.

Wilson SM, Maes AP, Yeoman CJ, Walk ST, Miles MP. Determinants of the postprandial triglyceride response to a high-fat meal in healthy overweight and obese adults. Lipids Health Dis. 2021;20(1):107. https://doi.org/10.1186/s12944-021-01543-4.CrossRefPubMedPubMedCentral

19.

Zeljkovic A, Vekic J, Mihajlovic M, Gojkovic T, Vladimirov S, Zeljkovic D, et al. Revealing the role of high-density lipoprotein in colorectal cancer. Int J Mol Sci. 2021;22(7). https://doi.org/10.3390/ijms22073352.

20.

Stadler JT, Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function. Int J Mol Sci. 2020;21(23). https://doi.org/10.3390/ijms21238985.

21.

• Ginsberg HN, Packard CJ, Chapman MJ, Boren J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791–806. https://doi.org/10.1093/eurheartj/ehab551. Recent advances on the metabolism, structure, and role of triglyceride-rich lipoproteins in atherosclerosis.

22.

Vekic J, Zeljkovic A, Stefanovic A, Bogavac-Stanojevic N, Ilias I, Silva-Nunes J, et al. Novel pharmaceutical and nutraceutical-based approaches for cardiovascular diseases prevention targeting atherogenic small dense LDL. Pharmaceutics. 2022;14(4). https://doi.org/10.3390/pharmaceutics14040825.

23.

Murawska K, Krintus M, Kuligowska-Prusinska M, Szternel L, Stefanska A, Sypniewska G. Relationship between serum angiopoietin-like proteins 3 and 8 and atherogenic lipid biomarkers in non-diabetic adults depends on gender and obesity. Nutrients. 2021;13(12). https://doi.org/10.3390/nu13124339.

24.

Lejawa M, Osadnik K, Czuba Z, Osadnik T, Pawlas N. Association of metabolically healthy and unhealthy obesity phenotype with markers related to obesity, diabetes among young, healthy adult men. Analysis of MAGNETIC Study. Life (Basel). 2021;11(12). https://doi.org/10.3390/life11121350.

25.

Paola Gutierrez Castro K, Patricia Gonzalez A, Caccavello R, Garay-Sevilla ME, Gugliucci A. Lean adolescents with insulin resistance display higher angiopoietin like protein 3, ApoC-III and chylomicron remnant dyslipidemia. Clin Chim Acta. 2022;526:43–8. https://doi.org/10.1016/j.cca.2021.12.016.

26.

Rodriguez-Mortera R, Caccavello R, Garay-Sevilla ME, Gugliucci A. Higher ANGPTL3, apoC-III, and apoB48 dyslipidemia, and lower lipoprotein lipase concentrations are associated with dysfunctional visceral fat in adolescents with obesity. Clin Chim Acta. 2020;508:61–8. https://doi.org/10.1016/j.cca.2020.05.014.CrossRefPubMed

27.

Garces MF, Rodriguez-Navarro HA, Buell-Acosta JD, Burgos-Cardenas AJ, Franco-Vega R, Maldonado-Acosta LM, et al. Maternal serum angiopoietin-like 3 levels in healthy and mild preeclamptic pregnant women. Front Endocrinol (Lausanne). 2021;12:670357. https://doi.org/10.3389/fendo.2021.670357.

28.

Vekic J, Zeljkovic A, Al Rasadi K, Cesur M, Silva-Nunes J, Stoian AP, et al. A New look at novel cardiovascular risk biomarkers: the role of atherogenic lipoproteins and innovative antidiabetic therapies. Metabolites. 2022;12(2). https://doi.org/10.3390/metabo12020108.

29.

Superko H, Garrett B. Small dense LDL: scientific background, clinical relevance, and recent evidence still a risk even with ‘normal’ LDL-C levels. Biomedicines. 2022;10(4). https://doi.org/10.3390/biomedicines10040829.

30.

Vekic J, Vujcic S, Bufan B, Bojanin D, Al-Hashmi K, Al-Rasadi K, et al. The role of advanced glycation end products on dyslipidemia. Metabolites. 2023;13(1). https://doi.org/10.3390/metabo13010077.

31.

Bekhet OH, Zeljkovic A, Vekic J, Paripovic D, Janac J, Joksic J, et al. Hypertension, lipoprotein subclasses and lipid transfer proteins in obese children and adolescents. Scand J Clin Lab Invest. 2016;76(6):472–8. https://doi.org/10.1080/00365513.2016.1201849.CrossRefPubMed

32.

Bekhet OH, Vekic J, Zeljkovic A, Paripovic D, Gojkovic T, Janac J, et al. Associations of Apgar score and size at birth with lipoprotein subclasses in juvenile obesity. Turk J Med Sci. 2017;47(6):1804–12. https://doi.org/10.3906/sag-1702-164.CrossRefPubMed

33.

Siurana JM, Sabate-Rotes A, Amigo N, Martinez-Micaelo N, Arciniegas L, Riaza L, et al. Different profiles of lipoprotein particles associate various degrees of cardiac involvement in adolescents with morbid obesity. Front Pediatr. 2022;10:887771. https://doi.org/10.3389/fped.2022.887771.

34.

Janac JM, Zeljkovic A, Jelic-Ivanovic ZD, Dimitrijevic-Sreckovic VS, Vekic J, Miljkovic MM, et al. Increased oxidized high-density lipoprotein/high-density lipoprotein-cholesterol ratio as a potential indicator of disturbed metabolic health in overweight and obese individuals. Lab Med. 2020;51(1):24–33. https://doi.org/10.1093/labmed/lmz017.CrossRefPubMed

35.

Tsatsoulis A, Paschou SA. Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences. Curr Obes Rep. 2020;9(2):109–20. https://doi.org/10.1007/s13679-020-00375-0.CrossRefPubMed

36.

Zembic A, Eckel N, Stefan N, Baudry J, Schulze MB. An empirically derived definition of metabolically healthy obesity based on risk of cardiovascular and total mortality. JAMA Netw Open. 2021;4(5):e218505. https://doi.org/10.1001/jamanetworkopen.2021.8505.

37.

• Telle-Hansen VH, Christensen JJ, Formo GA, Holven KB, Ulven SM. A comprehensive metabolic profiling of the metabolically healthy obesity phenotype. Lipids Health Dis. 2020;19(1):90. https://doi.org/10.1186/s12944-020-01273-z. A detailed metabolic profiling of metabolically healthy and unhealthy obesity phenotypes may improve prevention of cardiometabolic diseases.CrossRefPubMedPubMedCentral

38.

Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease. J Am Coll Cardiol. 2020;75(17):2122–35. https://doi.org/10.1016/j.jacc.2020.02.059.CrossRefPubMedPubMedCentral

39.

Hori M, Imamura T, Narang N, Onoda H, Tanaka S, Ushijima R, et al. Triglyceride and small dense LDL-cholesterol in patients with acute coronary syndrome. J Clin Med. 2021;10(19). https://doi.org/10.3390/jcm10194607.

40.

Bernelot Moens SJ, Verweij SL, Schnitzler JG, Stiekema LCA, Bos M, Langsted A, et al. Remnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humans. Arterioscler Thromb Vasc Biol. 2017;37(5):969–75. https://doi.org/10.1161/ATVBAHA.116.308834.CrossRefPubMed

41.

Nakajima K, Tokita Y, Tanaka A. Hypothesis: postprandial remnant lipoproteins are the causal factors that induce the insulin resistance associated with obesity. Clin Chim Acta. 2018;485:126–32. https://doi.org/10.1016/j.cca.2018.06.029.CrossRefPubMed

42.

Varbo A, Freiberg JJ, Nordestgaard BG. Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the copenhagen general population study. Clin Chem. 2018;64(1):219–30. https://doi.org/10.1373/clinchem.2017.279463.CrossRefPubMed

43.

Zou Y, Lan J, Zhong Y, Yang S, Zhang H, Xie G. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study. Lipids Health Dis. 2021;20(1):139. https://doi.org/10.1186/s12944-021-01573-y.CrossRefPubMedPubMedCentral

44.

Wei D, Marrachelli VG, Melgarejo JD, Liao CT, Janssens S, Verhamme P, et al. Lipoprotein profiles of fat distribution and its association with insulin sensitivity. Front Endocrinol (Lausanne). 2022;13:978745. https://doi.org/10.3389/fendo.2022.978745.

45.

Zou Y, Kuang M, Zhong Y, Jiang C. Remnant cholesterol can identify individuals at higher risk of metabolic syndrome in the general population. Sci Rep. 2023;13(1):5957. https://doi.org/10.1038/s41598-023-33276-y.CrossRefPubMedPubMedCentral

46.

Chin J, Mori TA, Adams LA, Beilin LJ, Huang RC, Olynyk JK, et al. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents. JHEP Rep. 2020;2(6):100150. https://doi.org/10.1016/j.jhepr.2020.100150.

47.

Tong J, Li X, Liang X, Tang F, Ren Y, Hao G, et al. The relationship of remnant cholesterol and abdominal obesity in children: a cross-sectional study. Front Cardiovasc Med. 2022;9:929560. https://doi.org/10.3389/fcvm.2022.929560.

48.

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. https://doi.org/10.1093/eurheartj/ehab484.CrossRefPubMed

49.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.CrossRefPubMed

50.

Mihuta MS, Stoian D, Borlea A, Roi CM, Velea-Barta OA, Mozos I, et al. Evaluating the arterial stiffness as a useful tool in the management of obese children. Children (Basel). 2023;10(2). https://doi.org/10.3390/children10020183.

51.

Hirschler V, Lapertosa S, Raquel Scaiola E, Garcia C, Maldonado N, Guntsche Z, et al. Adiposity, lifestyle behaviors, and cardiometabolic markers in Argentinean schoolchildren. Clin Chim Acta. 2020;507:280–5. https://doi.org/10.1016/j.cca.2020.05.008.CrossRefPubMed

52.

Lechner K, McKenzie AL, Krankel N, Von Schacky C, Worm N, Nixdorff U, et al. High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation. Metab Syndr Relat Disord. 2020;18(4):176–85. https://doi.org/10.1089/met.2019.0115.CrossRefPubMedPubMedCentral

53.

Sadana P, Lin L, Aghayev M, Ilchenko S, Kasumov T. Early pro-inflammatory remodeling of HDL proteome in a model of diet-induced obesity: (2)H(2)O-metabolic labeling-based kinetic approach. Int J Mol Sci. 2020;21(20). https://doi.org/10.3390/ijms21207472.

54.

Ji A, Trumbauer AC, Noffsinger VP, Jeon H, Patrick AC, De Beer FC, et al. Serum Amyloid A is not obligatory for high-fat, high-sucrose, cholesterol-fed diet-induced obesity and its metabolic and inflammatory complications. PLoS One. 2022;17(4):e0266688. https://doi.org/10.1371/journal.pone.0266688.

55.

Han CY, Kang I, Omer M, Wang S, Wietecha T, Wight TN, et al. Serum amyloid A-containing HDL binds adipocyte-derived versican and macrophage-derived biglycan, reducing its antiinflammatory properties. JCI Insight. 2020;5(20). https://doi.org/10.1172/jci.insight.142635.

56.

Zhang T, Chen J, Tang X, Luo Q, Xu D, Yu B. Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis. Lipids Health Dis. 2019;18(1):223. https://doi.org/10.1186/s12944-019-1170-9.CrossRefPubMedPubMedCentral

57.

Kotur-Stevuljevic J, Vekic J, Stefanovic A, Zeljkovic A, Ninic A, Ivanisevic J, et al. Paraoxonase 1 and atherosclerosis-related diseases. BioFactors. 2020;46(2):193–205. https://doi.org/10.1002/biof.1549.CrossRefPubMed

58.

Kupczyk D, Bilski R, Sokolowski K, Pawlowska M, Wozniak A, Szewczyk-Golec K. Paraoxonase 1: the lectin-like oxidized LDL receptor type I and oxidative stress in the blood of men with type II obesity. Dis Markers. 2019;2019:6178017. https://doi.org/10.1155/2019/6178017.CrossRefPubMedPubMedCentral

59.

Cervellati C, Bonaccorsi G, Trentini A, Valacchi G, Sanz JM, Squerzanti M, et al. Paraoxonase, arylesterase and lactonase activities of paraoxonase-1 (PON1) in obese and severely obese women. Scand J Clin Lab Invest. 2018;78(1–2):18–24. https://doi.org/10.1080/00365513.2017.1405274.CrossRefPubMed

60.

Diels S, Cuypers B, Tvarijonaviciute A, Derudas B, Van Dijck E, Verrijken A, et al. A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease. Clin Epigenetics. 2021;13(1):158. https://doi.org/10.1186/s13148-021-01142-1.CrossRefPubMedPubMedCentral

61.

Janac J, Zeljkovic A, Jelic-Ivanovic Z, Dimitrijevic-Sreckovic V, Miljkovic M, Stefanovic A, et al. The association between lecithin-cholesterol acyltransferase activity and fatty liver index. Ann Clin Biochem. 2019;56(5):583–92. https://doi.org/10.1177/0004563219853596.CrossRefPubMed

62.

• Stadler JT, Lackner S, Morkl S, Trakaki A, Scharnagl H, Borenich A, et al. Obesity affects HDL metabolism, composition and subclass distribution. Biomedicines. 2021;9(3). https://doi.org/10.3390/biomedicines9030242. Obesity provokes substantial changes in HDL proteome and lipidome, HDL-modeling enzymes, and HDL subclasses' distribution.

63.

Nass KJ, van den Berg EH, Gruppen EG, Dullaart RPF. Plasma lecithin:cholesterol acyltransferase and phospholipid transfer protein activity independently associate with nonalcoholic fatty liver disease. Eur J Clin Invest. 2018;48(9):e12988. https://doi.org/10.1111/eci.12988.

64.

Mocciaro G, D’Amore S, Jenkins B, Kay R, Murgia A, Herrera-Marcos LV, et al. Lipidomic approaches to study HDL metabolism in patients with central obesity diagnosed with metabolic syndrome. Int J Mol Sci. 2022;23(12). https://doi.org/10.3390/ijms23126786.

65.

• Stadler JT, van Poppel MNM, Wadsack C, Holzer M, Pammer A, Simmons D, et al. Obesity affects maternal and neonatal HDL metabolism and function. Antioxidants (Basel). 2023;12(1). https://doi.org/10.3390/antiox12010199. Obesity prior pregnancy is linked to lower serum antioxidant capacity and LCAT activity in both mothers and offspring, and higher cholesterol efflux capacity in mothers.

66.

Blauw LL, de Mutsert R, Lamb HJ, de Roos A, Rosendaal FR, Jukema JW, et al. Serum CETP concentration is not associated with measures of body fat: the NEO study. Atherosclerosis. 2016;246:267–73. https://doi.org/10.1016/j.atherosclerosis.2016.01.031.CrossRefPubMed

67.

Song G, Zong C, Shao M, Yu Y, Liu Q, Wang H, et al. Phospholipid transfer protein (PLTP) deficiency attenuates high fat diet induced obesity and insulin resistance. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(10):1305–13. https://doi.org/10.1016/j.bbalip.2019.06.012.CrossRefPubMed

68.

Vaisar T, Wang S, Omer M, Irwin AD, Storey C, Tang C, et al. 10,12-Conjugated linoleic acid supplementation improves HDL composition and function in mice. J Lipid Res. 2022;63(8):100241. https://doi.org/10.1016/j.jlr.2022.100241.

69.

Davidson WS, Heink A, Sexmith H, Dolan LM, Gordon SM, Otvos JD, et al. Obesity is associated with an altered HDL subspecies profile among adolescents with metabolic disease. J Lipid Res. 2017;58(9):1916–23. https://doi.org/10.1194/jlr.M078667.CrossRefPubMedPubMedCentral

70.

Akiyama H, Iwata F, Okada T. Lipoprotein-subclass particle numbers in children with abdominal obesity. Pediatr Int. 2022;64(1):e15045. https://doi.org/10.1111/ped.15045.

71.

Woudberg NJ, Lecour S, Goedecke JH. HDL subclass distribution shifts with increasing central adiposity. J Obes. 2019;2019:2107178. https://doi.org/10.1155/2019/2107178.CrossRefPubMedPubMedCentral

72.

Woudberg NJ, Mendham AE, Katz AA, Goedecke JH, Lecour S. Exercise intervention alters HDL subclass distribution and function in obese women. Lipids Health Dis. 2018;17(1):232. https://doi.org/10.1186/s12944-018-0879-1.CrossRefPubMedPubMedCentral

73.

Pedersen LR, Olsen RH, Anholm C, Astrup A, Eugen-Olsen J, Fenger M, et al. Effects of 1 year of exercise training versus combined exercise training and weight loss on body composition, low-grade inflammation and lipids in overweight patients with coronary artery disease: a randomized trial. Cardiovasc Diabetol. 2019;18(1):127. https://doi.org/10.1186/s12933-019-0934-x.CrossRefPubMedPubMedCentral

74.

Ohman EA, Kirchner L, Winkvist A, Bertz F, Holven KB, Ulven SM, et al. Effects of dietary and exercise treatments on HDL subclasses in lactating women with overweight and obesity: a secondary analysis of a randomised controlled trial. Br J Nutr. 2022;128(11):2105–14. https://doi.org/10.1017/S0007114522000241.CrossRefPubMedPubMedCentral

75.

• Tang H, Xiang Z, Li L, Shao X, Zhou Q, You X, et al. Potential role of anti-inflammatory HDL subclasses in metabolic unhealth/obesity. Artif Cells Nanomed Biotechnol. 2021;49(1):565–75. https://doi.org/10.1080/21691401.2021.1961798. Metabolically unhealthy obesity is characterized by the redistribution of HDL subclasses toward lower prevalence of HDL 2b particles. These particles might act anti-inflammatory.CrossRefPubMed

76.

Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38(32):2478–86. https://doi.org/10.1093/eurheartj/ehx163.CrossRefPubMed

77.

von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2023;44(16):1394–407. https://doi.org/10.1093/eurheartj/ehac605.CrossRef

78.

Madsen CM, Varbo A, Nordestgaard BG. Novel insights from human studies on the role of high-density lipoprotein in mortality and noncardiovascular disease. Arterioscler Thromb Vasc Biol. 2021;41(1):128–40. https://doi.org/10.1161/ATVBAHA.120.314050.CrossRefPubMed

79.

Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal JF, Montagner A, et al. Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia. 2020;63(3):453–61. https://doi.org/10.1007/s00125-019-05040-3.CrossRefPubMed

80.

Yan H, Yang W, Zhou F, Li X, Pan Q, Shen Z, et al. Estrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor Foxo1. Diabetes. 2019;68(2):291–304. https://doi.org/10.2337/db18-0638.CrossRefPubMed

81.

Stanek A, Grygiel-Gorniak B, Brozyna-Tkaczyk K, Myslinski W, Cholewka A, Zolghadri S. The influence of dietary interventions on arterial stiffness in overweight and obese subjects. Nutrients. 2023;15(6). https://doi.org/10.3390/nu15061440.

82.

Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261–71. https://doi.org/10.4103/jhrs.JHRS_95_18.CrossRefPubMedPubMedCentral

83.

Chiaffarino F, Cipriani S, Dalmartello M, Ricci E, Esposito G, Fedele F, et al. Prevalence of polycystic ovary syndrome in European countries and USA: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022;279:159–70. https://doi.org/10.1016/j.ejogrb.2022.10.020.CrossRefPubMed

84.

Parker J, O’Brien C, Hawrelak J, Gersh FL. Polycystic ovary syndrome: an evolutionary adaptation to lifestyle and the environment. Int J Environ Res Public Health. 2022;19(3). https://doi.org/10.3390/ijerph19031336.

85.

Rababa’h AM, Matani BR, Yehya A. An update of polycystic ovary syndrome: causes and therapeutics options. Heliyon. 2022;8(10):e11010. https://doi.org/10.1016/j.heliyon.2022.e11010.

86.

Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668–80. https://doi.org/10.1016/S2213-8587(22)00163-2.CrossRefPubMed

87.

Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf). 2021;95(4):531–41. https://doi.org/10.1111/cen.14421.CrossRefPubMed

88.

Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. Indian J Endocrinol Metab. 2019;23(3):326–31. https://doi.org/10.4103/ijem.IJEM_30_19.CrossRefPubMedPubMedCentral

89.

Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042. https://doi.org/10.1177/1179558119874042.CrossRefPubMedPubMedCentral

90.

Shabbir S, Khurram E, Moorthi VS, Eissa YTH, Kamal MA, Butler AE. The interplay between androgens and the immune response in polycystic ovary syndrome. J Transl Med. 2023;21(1):259. https://doi.org/10.1186/s12967-023-04116-4.CrossRefPubMedPubMedCentral

91.

Xing C, Zhang J, Zhao H, He B. Effect of sex hormone-binding globulin on polycystic ovary syndrome: mechanisms, manifestations, genetics, and treatment. Int J Womens Health. 2022;14:91–105. https://doi.org/10.2147/IJWH.S344542.CrossRefPubMedPubMedCentral

92.

Calcaterra V, Verduci E, Cena H, Magenes VC, Todisco CF, Tenuta E, et al. Polycystic ovary syndrome in insulin-resistant adolescents with obesity: the role of nutrition therapy and food supplements as a strategy to protect fertility. Nutrients. 2021;13(6). https://doi.org/10.3390/nu13061848.

93.

Wu C, Wei K, Jiang Z. 5alpha-reductase activity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2017;15(1):21. https://doi.org/10.1186/s12958-017-0242-9.CrossRefPubMedPubMedCentral

94.

Luo X, Cai WY, Wu XK. Prevalence, pattern and predictors for dyslipidemia of Chinese women with polycystic ovary syndrome. Front Cardiovasc Med. 2021;8:790454. https://doi.org/10.3389/fcvm.2021.790454.

95.

Pan JX, Tan YJ, Wang FF, Hou NN, Xiang YQ, Zhang JY, et al. Aberrant expression and DNA methylation of lipid metabolism genes in PCOS: a new insight into its pathogenesis. Clin Epigenetics. 2018;10:6. https://doi.org/10.1186/s13148-018-0442-y.CrossRefPubMedPubMedCentral

96.

Spalkowska M, Mrozinska S, Galuszka-Bednarczyk A, Gosztyla K, Przywara A, Guzik J, et al. The PCOS patients differ in lipid profile according to their phenotypes. Exp Clin Endocrinol Diabetes. 2018;126(7):437–44. https://doi.org/10.1055/s-0043-121264.CrossRefPubMed

97.

Liu Q, Xie YJ, Qu LH, Zhang MX, Mo ZC. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2019;58(4):447–53. https://doi.org/10.1016/j.tjog.2019.05.003.CrossRefPubMed

98.

Perovic Blagojevic IM, Vekic JZ, Macut DP, Ignjatovic SD, Miljkovic-Trailovic MM, Zeljkovic AR, et al. Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia. Br J Nutr. 2022;128(4):604–12. https://doi.org/10.1017/S0007114521003585.CrossRefPubMed

99.

• Vatannejad A, Salimi F, Moradi N, Fouani FZ, Zandieh Z, Ansaripour S, et al. Evaluation of angiopoietin-like protein 3 (ANGPTL3) levels in polycystic ovary syndrome. Life Sci. 2020;263:118595. https://doi.org/10.1016/j.lfs.2020.118595. ANGPTL3 is associated with dyslipidemia in PCOS patients, plays a role in pathogenesis of PCOS, and needs to be further investigated as a potential therapeutic target in the treatment of PCOS.

100.

Samino S, Vinaixa M, Diaz M, Beltran A, Rodriguez MA, Mallol R, et al. Metabolomics reveals impaired maturation of HDL particles in adolescents with hyperinsulinaemic androgen excess. Sci Rep. 2015;5:11496. https://doi.org/10.1038/srep11496.CrossRefPubMedPubMedCentral

101.

Butler AE, Moin ASM, Reiner Z, Sathyapalan T, Jamialahmadi T, Sahebkar A, et al. HDL-associated proteins in subjects with polycystic ovary syndrome: a proteomic study. Cells. 2023;12(6). https://doi.org/10.3390/cells12060855.

102.

Devlieger R, Benhalima K, Damm P, Van Assche A, Mathieu C, Mahmood T, et al. Maternal obesity in Europe: where do we stand and how to move forward?: a scientific paper commissioned by the European Board and College of Obstetrics and Gynaecology (EBCOG). Eur J Obstet Gynecol Reprod Biol. 2016;201:203–8. https://doi.org/10.1016/j.ejogrb.2016.04.005.CrossRefPubMed

103.

Alfadhli EM. Maternal obesity influences birth weight more than gestational diabetes author. BMC Pregnancy Childbirth. 2021;21(1):111. https://doi.org/10.1186/s12884-021-03571-5.CrossRefPubMedPubMedCentral

104.

Wang AM, Lee AJ, Clark SM. The effects of overweight and obesity on pregnancy-related morbidity. Clin Exp Obstet Gynecol 2021;48(5):999–1009. https://doi.org/10.31083/j.ceog4805161.

105.

Hauspurg A, Ying W, Hubel CA, Michos ED, Ouyang P. Adverse pregnancy outcomes and future maternal cardiovascular disease. Clin Cardiol. 2018;41(2):239–46. https://doi.org/10.1002/clc.22887.CrossRefPubMedPubMedCentral

106.

Parrettini S, Caroli A, Torlone E. Nutrition and metabolic adaptations in physiological and complicated pregnancy: focus on obesity and gestational diabetes. Front Endocrinol (Lausanne). 2020;11:611929. https://doi.org/10.3389/fendo.2020.611929.

107.

Bucher M, Montaniel KRC, Myatt L, Weintraub S, Tavori H, Maloyan A. Dyslipidemia, insulin resistance, and impairment of placental metabolism in the offspring of obese mothers. J Dev Orig Health Dis. 2021;12(5):738–47. https://doi.org/10.1017/S2040174420001026.CrossRefPubMed

108.

Barrett HL, Dekker Nitert M, McIntyre HD, Callaway LK. Normalizing metabolism in diabetic pregnancy: is it time to target lipids? Diabetes Care. 2014;37(5):1484–93. https://doi.org/10.2337/dc13-1934.CrossRefPubMed

109.

Nasioudis D, Doulaveris G, Kanninen TT. Dyslipidemia in pregnancy and maternal-fetal outcome. Minerva Ginecol. 2019;71(2):155–62. https://doi.org/10.23736/S0026-4784.18.04330-7.CrossRefPubMed

110.

Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016;27(2):89–94. https://doi.org/10.5830/CVJA-2016-021.CrossRefPubMedPubMedCentral

111.

Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. Am J Epidemiol. 2014;180(4):346–58. https://doi.org/10.1093/aje/kwu145.CrossRefPubMedPubMedCentral

112.

Bever AM, Mumford SL, Schisterman EF, Sjaarda L, Perkins NJ, Gerlanc N, et al. Maternal preconception lipid profile and gestational lipid changes in relation to birthweight outcomes. Sci Rep. 2020;10(1):1374. https://doi.org/10.1038/s41598-019-57373-z.CrossRefPubMedPubMedCentral

113.

Dash S, Tiwari M, Dash P, Kar K, Mohakud NK. Complications of hypertriglyceridemia in pregnancy and its impact on neonates: a hospital-based study from Odisha. Cureus. 2022;14(8):e28399. https://doi.org/10.7759/cureus.28399.

114.

Bao W, Dar S, Zhu Y, Wu J, Rawal S, Li S, et al. Plasma concentrations of lipids during pregnancy and the risk of gestational diabetes mellitus: a longitudinal study. J Diabetes. 2018;10(6):487–95. https://doi.org/10.1111/1753-0407.12563.CrossRefPubMed

115.

Ardalic D, Stefanovic A, Banjac G, Cabunac P, Miljkovic M, Mandic-Markovic V, et al. Lipid profile and lipid oxidative modification parameters in the first trimester of high- risk pregnancies - possibilities for preeclampsia prediction. Clin Biochem. 2020;81:34–40. https://doi.org/10.1016/j.clinbiochem.2020.05.003.CrossRefPubMed

116.

Duttaroy AK, Basak S. Maternal fatty acid metabolism in pregnancy and its consequences in the feto-placental development. Front Physiol. 2021;12:787848. https://doi.org/10.3389/fphys.2021.787848.

117.

Zeljkovic A, Vekic J, Spasic S, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Gojkovic T, et al. Changes in LDL and HDL subclasses in normal pregnancy and associations with birth weight, birth length and head circumference. Matern Child Health J. 2013;17(3):556–65. https://doi.org/10.1007/s10995-012-1031-x.CrossRefPubMed

118.

Chen Y, Du M, Xu J, Chen D. The small dense LDL particle/large buoyant LDL particle ratio is associated with glucose metabolic status in pregnancy. Lipids Health Dis. 2017;16(1):244. https://doi.org/10.1186/s12944-017-0627-y.CrossRefPubMedPubMedCentral

119.

Gohil JT, Patel PK, Gupta P. Estimation of lipid profile in subjects of preeclampsia. J Obstet Gynaecol India. 2011;61(4):399–403. https://doi.org/10.1007/s13224-011-0057-0.CrossRefPubMedPubMedCentral

120.

Zeljkovic A, Ardalic D, Vekic J, Antonic T, Vladimirov S, Rizzo M, et al. Effects of gestational diabetes mellitus on cholesterol metabolism in women with high-risk pregnancies: possible implications for neonatal outcome. Metabolites. 2022;12(10). https://doi.org/10.3390/metabo12100959.

121.

Rideout TC, Wen X, Choudhary D, Catanzaro M, Browne RW, Barnabei VM, et al. Associations of maternal lipoprotein particle distribution in mid-pregnancy with birth outcomes: a pilot study. Lipids Health Dis. 2022;21(1):53. https://doi.org/10.1186/s12944-022-01664-4.CrossRefPubMedPubMedCentral

122.

Liao S, Wu H, Chen R. Apolipoprotein A1 mimetic peptide ATI-5261 reverses arterial stiffness at late pregnancy and early postpartum in a COMT(-/-) mouse model of preeclampsia. Clin Hypertens. 2018;24:11. https://doi.org/10.1186/s40885-018-0097-1.CrossRefPubMedPubMedCentral

123.

Melhem H, Kallol S, Huang X, Luthi M, Ontsouka CE, Keogh A, et al. Placental secretion of apolipoprotein A1 and E: the anti-atherogenic impact of the placenta. Sci Rep. 2019;9(1):6225. https://doi.org/10.1038/s41598-019-42522-1.CrossRefPubMedPubMedCentral

124.

Pasternak Y, Biron-Shental T, Ohana M, Einbinder Y, Arbib N, Benchetrit S, et al. Gestational diabetes type 2: variation in high-density lipoproteins composition and function. Int J Mol Sci. 2020;21(17). https://doi.org/10.3390/ijms21176281.

125.

Del Gaudio I, Hendrix S, Christoffersen C, Wadsack C. Neonatal HDL Counteracts placental vascular inflammation via S1P-S1PR1 axis. Int J Mol Sci. 2020;21(3). https://doi.org/10.3390/ijms21030789.

126.

Stadler JT, van Poppel MNM, Christoffersen C, Hill D, Wadsack C, Simmons D, et al. Gestational hypertension and high-density lipoprotein function: an explorative study in overweight/obese women of the DALI cohort. Antioxidants (Basel). 2022;12(1). https://doi.org/10.3390/antiox12010068.

127.

Lewek J, Banach M. Dyslipidemia management in pregnancy: why is it not covered in the guidelines? Curr Atheroscler Rep. 2022;24(7):547–56. https://doi.org/10.1007/s11883-022-01030-w.CrossRefPubMed

128.

Marshall NE, Abrams B, Barbour LA, Catalano P, Christian P, Friedman JE, et al. The importance of nutrition in pregnancy and lactation: lifelong consequences. Am J Obstet Gynecol. 2022;226(5):607–32. https://doi.org/10.1016/j.ajog.2021.12.035.CrossRefPubMed

129.

Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1–8.

130.

Marlatt KL, Pitynski-Miller DR, Gavin KM, Moreau KL, Melanson EL, Santoro N, et al. Body composition and cardiometabolic health across the menopause transition. Obesity (Silver Spring). 2022;30(1):14–27. https://doi.org/10.1002/oby.23289.CrossRefPubMed

131.

Ko SH, Kim HS. Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women. Nutrients. 2020;12(1). https://doi.org/10.3390/nu12010202.

132.

El Khoudary SR, Chen X, Nasr AN, Billheimer J, Brooks MM, McConnell D, et al. HDL (high-density lipoprotein) subclasses, lipid content, and function trajectories across the menopause transition: SWAN-HDL study. Arterioscler Thromb Vasc Biol. 2021;41(2):951–61. https://doi.org/10.1161/ATVBAHA.120.315355.CrossRefPubMed

133.

Izumida T, Nakamura Y, Sato Y, Ishikawa S. Association among age, gender, menopausal status and small dense low-density lipoprotein cholesterol: a cross-sectional study. BMJ Open. 2021;11(2):e041613. https://doi.org/10.1136/bmjopen-2020-041613.

134.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143. https://doi.org/10.1161/CIR.0000000000000625.CrossRefPubMed

135.

Vladimirov S, Gojkovic T, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Determination of non-cholesterol sterols in serum and HDL fraction by LC/MS-MS: Significance of matrix-related interferences. J Med Biochem. 2020;39(3):299–308. https://doi.org/10.2478/jomb-2019-0044.CrossRefPubMedPubMedCentral

136.

Mashnafi S, Plat J, Mensink RP, Baumgartner S. Non-cholesterol sterol concentrations as biomarkers for cholesterol absorption and synthesis in different metabolic disorders: a systematic review. Nutrients. 2019;11(1). https://doi.org/10.3390/nu11010124.

137.

Zeljkovic A, Milojevic A, Vladimirov S, Zdravkovic M, Memon L, Brajkovic M, et al. Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: influence of obesity and disease severity. Nutr Metab Cardiovasc Dis. 2022;32(12):2848–57. https://doi.org/10.1016/j.numecd.2022.09.006.CrossRefPubMed

138.

Li ZZ, Huang Q, Yang XL, Zeng J, Wang QH, Tang HM, et al. Cholesterol metabolic markers for differential evaluation of patients with hyperlipidemia and familial hypercholesterolemia. Dis Markers. 2022;2022:2008556. https://doi.org/10.1155/2022/2008556.CrossRefPubMedPubMedCentral

139.

Gojkovic T, Vladimirov S, Spasojevic-Kalimanovska V, Zeljkovic A, Vekic J, Kalimanovska-Ostric D, et al. Can non-cholesterol sterols and lipoprotein subclasses distribution predict different patterns of cholesterol metabolism and statin therapy response? Clin Chem Lab Med. 2017;55(3):447–57. https://doi.org/10.1515/cclm-2016-0505.CrossRefPubMed

140.

Cho AR, Moon JY, Kim S, An KY, Oh M, Jeon JY, et al. Effects of alternate day fasting and exercise on cholesterol metabolism in overweight or obese adults: a pilot randomized controlled trial. Metabolism. 2019;93:52–60. https://doi.org/10.1016/j.metabol.2019.01.002.CrossRefPubMed

141.

Schroor MM, Plat J, Konings M, Smeets E, Mensink RP. Effect of dietary macronutrients on intestinal cholesterol absorption and endogenous cholesterol synthesis: a randomized crossover trial. Nutr Metab Cardiovasc Dis. 2021;31(5):1579–85. https://doi.org/10.1016/j.numecd.2021.01.010.CrossRefPubMed

142.

Liao GC, Jhuang JH, Yao HT. Artichoke leaf extract supplementation lowers hepatic oxidative stress and inflammation and increases multidrug resistance-associated protein 2 in mice fed a high-fat and high-cholesterol diet. Food Funct. 2021;12(16):7239–49. https://doi.org/10.1039/d1fo00861g.CrossRefPubMed

143.

Rahman ML, Feng YA, Fiehn O, Albert PS, Tsai MY, Zhu Y, et al. Plasma lipidomics profile in pregnancy and gestational diabetes risk: a prospective study in a multiracial/ethnic cohort. BMJ Open Diabetes Res Care. 2021;9(1). https://doi.org/10.1136/bmjdrc-2020-001551.

144.

• Zhang L, Bi S, Liang Y, Huang L, Li Y, Huang M, et al. Integrated metabolomic and lipidomic analysis in the placenta of preeclampsia. Front Physiol. 2022;13:807583. https://doi.org/10.3389/fphys.2022.807583. Advanced placental metabolomics and lipidomics profiling offer a significant and deeper insight in molecular mechanism underlying preeclampsia.

145.

Antonic TD, Ardalic DC, Vladimirov SS, Banjac GS, Cabunac PJ, Zeljkovic AR, et al. Cholesterol homeostasis is dysregulated in women with preeclampsia. Pol Arch Intern Med. 2021;131(12). https://doi.org/10.20452/pamw.16144.

Titel: Obesity and Dyslipidemia: A Review of Current Evidence
verfasst von: Jelena Vekic
Aleksandra Stefanovic
Aleksandra Zeljkovic
Publikationsdatum: 06.07.2023
Verlag: Springer US
Erschienen in: Current Obesity Reports / Ausgabe 3/2023
Elektronische ISSN: 2162-4968
DOI: https://doi.org/10.1007/s13679-023-00518-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Meta-analysis of Long-term De Novo Acid Reflux–Related Outcomes Following Sleeve Gastrectomy: Evidence Against the Need for Routine Postoperative Endoscopic Surveillance

Optimal Small Bowel Limb Lengths of Roux-en-Y Gastric Bypass

Behavioral and Psychological Factors Affecting Weight Loss Success

Medicolegal Cases in Bariatric Surgery in the United Kingdom

The Effectiveness of eHealth Interventions for Weight Loss and Weight Loss Maintenance in Adults with Overweight or Obesity: A Systematic Review of Systematic Reviews

The Influence of Single Nucleotide Polymorphisms On Body Weight Trajectory After Bariatric Surgery: A Systematic Review